Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial

Background. Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate to severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 trial. Aim. To evaluate the efficacy and safety of two...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Luis Puig, Andrey L. Bakulev, Muza M. Kokhan, Alexey V. Samtsov, Vladislav R. Khairutdinov, Maria A. Morozova, Nikita A. Zolkin, Ivan V. Kuryshev, Alexey N. Petrov, Antonina V. Artemeva, Arina V. Zinkina-Orikhan
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	State Scientific Center of Dermatovenereology and Cosmetology 2021-10-01
Reeks:	Vestnik Dermatologii i Venerologii
Onderwerpen:	psoriasis monoclonal antibodies interleukin-17 inhibitors
Online toegang:	https://vestnikdv.ru/jour/article/viewFile/1251/1234
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!